Q1 2025 Recursion Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Recursion Pharmaceuticals Inc (RXRX) has developed an advanced Recursion 2.0 platform, which integrates multimodal data and AI to enhance drug discovery and development efficiency.
- The company has successfully secured over $450 million through partnerships with major pharmaceutical companies like Sanofi and Roche Genentech, demonstrating strong external validation.
- Recursion Pharmaceuticals Inc (RXRX) is focusing on a more streamlined and strategic R&D portfolio, prioritizing programs with higher probabilities of success.
- The company has unveiled a pipeline with more than five clinical and preclinical programs, including promising candidates like REC-617 and REC1245, which show potential in oncology and rare diseases.
- Recursion Pharmaceuticals Inc (RXRX) is committed to disciplined capital allocation and has a cash runway extending into mid-2027, supported by strategic partnerships and efficient operational adjustments.
- The company has decided to discontinue several programs, including NF2, CCM, and C. diff, due to strategic considerations and lack of differentiation in the current market landscape.
- Recursion Pharmaceuticals Inc (RXRX) faces challenges in the macroeconomic environment, necessitating disciplined and thoughtful decision-making to ensure long-term sustainability.
- The FAP program, while showing some preliminary efficacy, still requires further investigation and data to fully understand its potential and address non-responder issues.
- The company is strategically pausing the development of the LSD1 program to reassess opportunities for a more differentiated target product profile.
- Recursion Pharmaceuticals Inc (RXRX) is navigating a competitive landscape in oncology and rare diseases, requiring continuous innovation and differentiation to maintain its market position.
Hi, everybody. My name is Chris Gibson, Co-Founder and CEO of Recursion, and I'm delighted to welcome you to our earnings call this morning. We're going to go ahead and get started.
Perfect. So of course, important to note that we're going to be providing forward-looking information today, so please understand all of these important caveats.
So I want to begin by just talking a little bit about Recursion's mission, which is to decode biology to radically improve lives. And unlike a traditional biotech, where learnings from a program typically work within that specific program, those learnings could improve a program, or the scientists from a given program might take some of those learnings onto their next program.
At Recursion, we're trying to do something different. We're trying to build a learning system, a Recursion operating system, that learns from every program to make the next generation of programs better and better, and that requires some scale. And what you're going to see today is
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
